Impala Nordic

Bifogade filer

OncoZenge Comment, 12 September 2025

Prenumeration

OncoZenge - Execution advancing for Phase III study with LINK Medical as CRO

2025-09-12 09:40:00

Impala Nordic comments the news that OncoZenge AB (“OncoZenge”) has appointed LINK Medical (“LINK”) as CRO for its upcoming European Phase III study.

OncoZenge has named LINK as CRO for its upcoming European Phase III study of BupiZenge™. Following a successful feasibility study by LINK, we view the appointment and the choice of Nordic and German sites as positive, in line with the previously communicated plan and timeline. The announcement also gives more details on the program.

Read the full comment here.

About Impala Nordic

Impala Nordic provides company analysis, coverage, and comprehensive investor relations (IR) services. The portfolio includes listed small-cap companies, where Impala Nordic acts as a communicative bridge between the companies and investors.

The material produced by Impala Nordic is independent but sponsored. This means that Impala Nordic has received payment from the client to produce the analysis and coverage. The client has not been able to influence Impala Nordic’s opinions expressed in the material.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Impala Nordic

Bifogade filer

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden